Mereo BioPharma Group Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2016
Revenue	-	10	0	45.58	0	0	Upgrade
Cost of Revenue	-	2.57	-1.15	22.39	0	0	Upgrade
Gross Profit	-	7.43	1.15	23.2	0	0	Upgrade
Selling, General & Admin	-	18.42	26.11	19.92	26.53	19.89	Upgrade
Research & Development	-	17.42	29.47	29.45	20.43	29.51	Upgrade
Other Operating Expenses	0	0	0	-0.14	13.59	0	Upgrade
Operating Expenses	-	35.84	55.57	49.22	60.55	49.4	Upgrade
Operating Income	-	-28.42	-54.43	-26.03	-60.55	-49.4	Upgrade
Interest Expense / Income	-	2.88	4.18	5.03	7.98	5.46	Upgrade
Other Expense / Income	-	-0.02	-13.94	-48.86	139.53	-3.46	Upgrade
Pretax Income	-	-31.28	-44.67	17.8	-208.06	-51.4	Upgrade
Income Tax	-	-1.81	-2.45	1.9	-3.53	-7.84	Upgrade
Net Income	-	-29.47	-42.22	15.91	-204.54	-43.56	Upgrade
Shares Outstanding (Basic)	700	659	603	545	339	71	Upgrade
Shares Outstanding (Diluted)	-	659	603	-	-	-	Upgrade
Shares Change	16.09%	9.33%	10.78%	60.76%	376.09%	-18.21%	Upgrade
EPS (Basic)	-	-0.20	-0.35	0.13	-3.00	-2.44	Upgrade
EPS (Diluted)	-	-0.20	-0.35	-0.31	-3.00	-2.44	Upgrade
Free Cash Flow	-	-21.13	-48.83	-7.22	-35.45	-57.44	Upgrade
Free Cash Flow Per Share	-	-0.16	-0.41	-0.07	-0.52	-4.04	Upgrade
Gross Margin	-	74.26%	-	50.89%	-	-	Upgrade
Operating Margin	-	-284.16%	-	-57.11%	-	-	Upgrade
Profit Margin	-	-294.66%	-	34.90%	-	-	Upgrade
Free Cash Flow Margin	-	-211.32%	-	-15.83%	-	-	Upgrade
Effective Tax Rate	-	-	-	10.65%	-	-	Upgrade
EBITDA	-	-27.34	-39.6	23.63	-198.09	-43.96	Upgrade
EBITDA Margin	-	-273.36%	-	51.85%	-	-	Upgrade
Depreciation & Amortization	-	1.06	0.89	0.8	2	1.97	Upgrade
EBIT	-	-28.4	-40.49	22.83	-200.08	-45.93	Upgrade
EBIT Margin	-	-283.97%	-	50.09%	-	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).